Shortsellers Say Gingko BioWorks Is ‘Colossal Synthetic Biology Scam'

One Of 2021’s Biggest Biotech IPOs

 
• By Andrew McConaghie
  
Gingko Bioworks
Gingko Bioworks believes its can serve as a research platform for the entire synthetic biology industry - but its business model has drawn skepticism. • Source: Gingko Bioworks
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip